Is Enhertu Effective for Lung Cancer?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
On January 20, 2022, Bob T. Li and colleagues from Memorial Sloan Kettering Cancer Center published the results of the Phase 2 DESTINY-Lung01 clinical trial in "The New England Journal of Medicine." The study evaluated the efficacy and safety of Enhertu monotherapy in patients with previously treated, HER2-positive advanced non-small cell lung cancer (NSCLC).
DESTINY-Lung01 is an international, multi-center, open-label Phase 2 trial. Patients with previously treated, HER2-positive advanced NSCLC (N=91) received Enhertu monotherapy (6.4 mg/kg every 3 weeks). The primary endpoint was objective response rate (ORR), and secondary endpoints included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS).
With a median follow-up of 13.1 months, the primary endpoint ORR was 55%. Secondary endpoints included a median DOR of 9.3 months, a median PFS of 8.2 months, and a median OS of 17.8 months.
Regarding safety, the adverse events confirmed in this trial were consistent with previous findings. The incidence of Grade 3 or higher adverse events was 46%, with neutropenia (19%) being the most common. Drug-related interstitial lung disease (ILD) occurred in 26% of patients, and two deaths were confirmed.
Based on the DESTINY-Lung01 results, Bob T. Li stated that Enhertu monotherapy demonstrated a durable and significant anti-tumor effect in patients with previously treated, HER2-positive advanced NSCLC, with a safety profile consistent with previous clinical trials.
Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2112431
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4